drugset / Trial / NCT02526888

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

NCT02526888

Phase 1 Completed 14 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

The main objective of this study is to investigate whether repeated administration of a cardiac medication (diltiazem) can affect the pharmacokinetics (i.e., amount and time of presence in the blood) of ACT-541468

Timeline

Start
2015-09-01
Primary completion
2015-11-01
Completion
2015-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg Oral
Subject Diltiazem Small molecule 240 mg Oral

Indications

No indication recorded.